<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35277554</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>11</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Mitochondrial dysregulation occurs early in ALS motor cortex with TDP-43 pathology and suggests maintaining NAD<sup>+</sup> balance as a therapeutic strategy.</ArticleTitle><Pagination><StartPage>4287</StartPage><MedlinePgn>4287</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4287</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-08068-5</ELocationID><Abstract><AbstractText>Mitochondrial defects result in dysregulation of metabolomics and energy homeostasis that are detected in upper motor neurons (UMNs) with TDP-43 pathology, a pathology that is predominantly present in both familial and sporadic cases of amyotrophic lateral sclerosis (ALS). While same mitochondrial problems are present in the UMNs of ALS patients with TDP-43 pathology and UMNs of TDP-43 mouse models, and since pathologies are shared at a cellular level, regardless of species, we first analyzed the metabolite profile of both healthy and diseased motor cortex to investigate whether metabolomic changes occur with respect to TDP-43 pathology. High-performance liquid chromatography, high-resolution mass spectrometry and tandem mass spectrometry (HPLC-MS/MS) for metabolite profiling began to suggest that reduced levels of NAD+ is one of the underlying causes of metabolomic problems. Since nicotinamide mononucleotide (NMN) was reported to restore NAD<sup>+</sup> levels, we next investigated whether NMN treatment would improve the health of diseased corticospinal motor neurons (CSMN, a.k.a. UMN in mice). prpTDP-43<sup>A315T</sup>-UeGFP mice, the CSMN reporter line with TDP-43 pathology, allowed cell-type specific responses of CSMN to NMN treatment to be assessed in vitro. Our results show that metabolomic defects occur early in ALS motor cortex and establishing NAD<sup>+</sup> balance could offer therapeutic benefit to UMNs with TDP-43 pathology.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gautam</LastName><ForeName>Mukesh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Ave, Chicago, IL, 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunay</LastName><ForeName>Aksu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Ave, Chicago, IL, 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandel</LastName><ForeName>Navdeep S</ForeName><Initials>NS</Initials><Identifier Source="ORCID">0000-0001-7208-3886</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozdinler</LastName><ForeName>P Hande</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Feinberg School of Medicine, Northwestern University, 303 E. Chicago Ave, Chicago, IL, 60611, USA. ozdinler@northwestern.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Molecular Innovation and Drug Discovery, Center for Developmental Therapeutics, Chemistry of Life Processes Institute, Northwestern University, Evanston, IL, 60611, USA. ozdinler@northwestern.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA. ozdinler@northwestern.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Feinberg School of Medicine, Les Turner ALS Center at Northwestern University, Chicago, IL, 60611, USA. ozdinler@northwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG061708</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0U46U6E8UK</RegistryNumber><NameOfSubstance UI="D009243">NAD</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="Y">Motor Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009243" MajorTopicYN="N">NAD</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>12</Day><Hour>5</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35277554</ArticleId><ArticleId IdType="pmc">PMC8917163</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-08068-5</ArticleId><ArticleId IdType="pii">10.1038/s41598-022-08068-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Benard G, et al. Mitochondrial bioenergetics and structural network organization. J. Cell Sci. 2007;120:838&#x2013;848. doi: 10.1242/jcs.03381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.03381</ArticleId><ArticleId IdType="pubmed">17298981</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimmer KS, Scorrano L. (De)constructing mitochondria: What for? Physiology (Bethesda) 2006;21:233&#x2013;241. doi: 10.1152/physiol.00010.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiol.00010.2006</ArticleId><ArticleId IdType="pubmed">16868312</ArticleId></ArticleIdList></Reference><Reference><Citation>Esterhuizen K, van der Westhuizen FH, Louw R. Metabolomics of mitochondrial disease. Mitochondrion. 2017;35:97&#x2013;110. doi: 10.1016/j.mito.2017.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2017.05.012</ArticleId><ArticleId IdType="pubmed">28576558</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinert EM, Vasan K, Chandel NS. Mitochondrial metabolism regulation of T cell-mediated immunity. Annu. Rev. Immunol. 2021;39:395&#x2013;416. doi: 10.1146/annurev-immunol-101819-082015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-101819-082015</ArticleId><ArticleId IdType="pubmed">33902315</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandel NS. Lipid metabolism. Cold Spring Harb. Perspect. Biol. 2021;13:a040576. doi: 10.1101/cshperspect.a040576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a040576</ArticleId><ArticleId IdType="pmc">PMC8411952</ArticleId><ArticleId IdType="pubmed">34470787</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigio EH, et al. TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease. Acta Neuropathol. 2010;120:43&#x2013;54. doi: 10.1007/s00401-010-0681-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0681-2</ArticleId><ArticleId IdType="pmc">PMC2903745</ArticleId><ArticleId IdType="pubmed">20361198</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Wang L, Huntley ML, Perry G, Wang X. Pathomechanisms of TDP-43 in neurodegeneration. J. Neurochem. 2018 doi: 10.1111/jnc.14327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14327</ArticleId><ArticleId IdType="pmc">PMC6110993</ArticleId><ArticleId IdType="pubmed">29486049</ArticleId></ArticleIdList></Reference><Reference><Citation>Nana AL, et al. Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. Acta Neuropathol. 2019;137:27&#x2013;46. doi: 10.1007/s00401-018-1942-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1942-8</ArticleId><ArticleId IdType="pmc">PMC6339592</ArticleId><ArticleId IdType="pubmed">30511086</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenouda M, Zhang AB, Weichert A, Robertson J. Mechanisms associated with TDP-43 neurotoxicity in ALS/FTLD. Adv. Neurobiol. 2018;20:239&#x2013;263. doi: 10.1007/978-3-319-89689-2_9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-89689-2_9</ArticleId><ArticleId IdType="pubmed">29916022</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Sampathu DM, Trojanowski JQ, Lee VM. TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis. Arch. Neurol. 2007;64:1388&#x2013;1394. doi: 10.1001/archneur.64.10.1388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.10.1388</ArticleId><ArticleId IdType="pubmed">17923623</ArticleId></ArticleIdList></Reference><Reference><Citation>Droppelmann CA, Campos-Melo D, Moszczynski AJ, Amzil H, Strong MJ. TDP-43 aggregation inside micronuclei reveals a potential mechanism for protein inclusion formation in ALS. Sci. Rep. 2019;9:19928. doi: 10.1038/s41598-019-56483-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-56483-y</ArticleId><ArticleId IdType="pmc">PMC6934605</ArticleId><ArticleId IdType="pubmed">31882736</ArticleId></ArticleIdList></Reference><Reference><Citation>Miguel L, Frebourg T, Campion D, Lecourtois M. Both cytoplasmic and nuclear accumulations of the protein are neurotoxic in Drosophila models of TDP-43 proteinopathies. Neurobiol. Dis. 2011;41:398&#x2013;406. doi: 10.1016/j.nbd.2010.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2010.10.007</ArticleId><ArticleId IdType="pubmed">20951205</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R. The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. Curr. Opin. Neurol. 2008;21:693&#x2013;700. doi: 10.1097/WCO.0b013e3283168d1d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e3283168d1d</ArticleId><ArticleId IdType="pmc">PMC2869081</ArticleId><ArticleId IdType="pubmed">18989115</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanelli T, et al. Evidence that TDP-43 is not the major ubiquitinated target within the pathological inclusions of amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2007;66:1147&#x2013;1153. doi: 10.1097/nen.0b013e31815c5edd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e31815c5edd</ArticleId><ArticleId IdType="pubmed">18090923</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, et al. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain. 2011;134:2610&#x2013;2626. doi: 10.1093/brain/awr159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr159</ArticleId><ArticleId IdType="pubmed">21752789</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam M, et al. Mitochondria, ER, and nuclear membrane defects reveal early mechanisms for upper motor neuron vulnerability with respect to TDP-43 pathology. Acta Neuropathol. 2019;137:47&#x2013;69. doi: 10.1007/s00401-018-1934-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1934-8</ArticleId><ArticleId IdType="pmc">PMC6339587</ArticleId><ArticleId IdType="pubmed">30450515</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam M, Xie EF, Kocak N, Ozdinler PH. Mitoautophagy: A unique self-destructive path mitochondria of upper motor neurons with TDP-43 pathology take, very early in ALS. Front. Cell. Neurosci. 2019;13:489. doi: 10.3389/fncel.2019.00489.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00489</ArticleId><ArticleId IdType="pmc">PMC6854036</ArticleId><ArticleId IdType="pubmed">31787882</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, et al. TDP-43 induces mitochondrial damage and activates the mitochondrial unfolded protein response. PLoS Genet. 2019;15:e1007947. doi: 10.1371/journal.pgen.1007947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1007947</ArticleId><ArticleId IdType="pmc">PMC6524796</ArticleId><ArticleId IdType="pubmed">31100073</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci. USA. 2009;106:18809&#x2013;18814. doi: 10.1073/pnas.0908767106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0908767106</ArticleId><ArticleId IdType="pmc">PMC2762420</ArticleId><ArticleId IdType="pubmed">19833869</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24:464&#x2013;471. doi: 10.1016/j.tcb.2014.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcb.2014.04.002</ArticleId><ArticleId IdType="pmc">PMC4112140</ArticleId><ArticleId IdType="pubmed">24786309</ArticleId></ArticleIdList></Reference><Reference><Citation>Mithal DS, Chandel NS. The Gro3p factor: Restoring NAD+/NADH homeostasis to ameliorate mitochondrial disease. Cell Metab. 2021;33:1905&#x2013;1907. doi: 10.1016/j.cmet.2021.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.09.006</ArticleId><ArticleId IdType="pubmed">34614406</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrador E, Salvador-Palmer R, Lopez-Blanch R, Dellinger RW, Estrela JM. NAD(+) precursors and antioxidants for the treatment of amyotrophic lateral sclerosis. Biomedicines. 2021;9:1000. doi: 10.3390/biomedicines9081000.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9081000</ArticleId><ArticleId IdType="pmc">PMC8394119</ArticleId><ArticleId IdType="pubmed">34440204</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki Y, Araki T, Milbrandt J. Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J. Neurosci. 2006;26:8484&#x2013;8491. doi: 10.1523/JNEUROSCI.2320-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2320-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674352</ArticleId><ArticleId IdType="pubmed">16914673</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava S. Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disorders. Clin. Transl. Med. 2016;5:25. doi: 10.1186/s40169-016-0104-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40169-016-0104-7</ArticleId><ArticleId IdType="pmc">PMC4963347</ArticleId><ArticleId IdType="pubmed">27465020</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdin E. NAD(+) in aging, metabolism, and neurodegeneration. Science. 2015;350:1208&#x2013;1213. doi: 10.1126/science.aac4854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aac4854</ArticleId><ArticleId IdType="pubmed">26785480</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14:528&#x2013;536. doi: 10.1016/j.cmet.2011.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2011.08.014</ArticleId><ArticleId IdType="pmc">PMC3204926</ArticleId><ArticleId IdType="pubmed">21982712</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CF, Caudal A, Abell L, Nagana Gowda GA, Tian R. Targeting NAD(+) metabolism as interventions for mitochondrial disease. Sci. Rep. 2019;9:3073. doi: 10.1038/s41598-019-39419-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-39419-4</ArticleId><ArticleId IdType="pmc">PMC6395802</ArticleId><ArticleId IdType="pubmed">30816177</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang Z, et al. MetaboAnalyst 5.0: Narrowing the gap between raw spectra and functional insights. Nucleic Acids Res. 2021;49:W388&#x2013;W396. doi: 10.1093/nar/gkab382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab382</ArticleId><ArticleId IdType="pmc">PMC8265181</ArticleId><ArticleId IdType="pubmed">34019663</ArticleId></ArticleIdList></Reference><Reference><Citation>Zitka O, et al. Redox status expressed as GSH:GSSG ratio as a marker for oxidative stress in paediatric tumour patients. Oncol. Lett. 2012;4:1247&#x2013;1253. doi: 10.3892/ol.2012.931.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ol.2012.931</ArticleId><ArticleId IdType="pmc">PMC3506742</ArticleId><ArticleId IdType="pubmed">23205122</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman HJ, Zhang H, Rinna A. Glutathione: Overview of its protective roles, measurement, and biosynthesis. Mol. Aspects Med. 2009;30:1&#x2013;12. doi: 10.1016/j.mam.2008.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mam.2008.08.006</ArticleId><ArticleId IdType="pmc">PMC2696075</ArticleId><ArticleId IdType="pubmed">18796312</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasvoina MV, et al. eGFP expression under UCHL1 promoter genetically labels corticospinal motor neurons and a subpopulation of degeneration-resistant spinal motor neurons in an ALS mouse model. J. Neurosci. 2013;33:7890&#x2013;7904. doi: 10.1523/JNEUROSCI.2787-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2787-12.2013</ArticleId><ArticleId IdType="pmc">PMC3963467</ArticleId><ArticleId IdType="pubmed">23637180</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozdinler PH, Macklis JD. IGF-I specifically enhances axon outgrowth of corticospinal motor neurons. Nat. Neurosci. 2006;9:1371&#x2013;1381. doi: 10.1038/nn1789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1789</ArticleId><ArticleId IdType="pubmed">17057708</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang T, et al. Amyotrophic lateral sclerosis mutant TDP-43 may cause synaptic dysfunction through altered dendritic spine function. Dis. Model Mech. 2019 doi: 10.1242/dmm.038109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.038109</ArticleId><ArticleId IdType="pmc">PMC6550035</ArticleId><ArticleId IdType="pubmed">31036551</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Gonzalez L, et al. Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1delta kinase inhibitor treatment. Sci. Rep. 2020;10:4449. doi: 10.1038/s41598-020-61265-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-61265-y</ArticleId><ArticleId IdType="pmc">PMC7064575</ArticleId><ArticleId IdType="pubmed">32157143</ArticleId></ArticleIdList></Reference><Reference><Citation>Briese M, et al. Loss of Tdp-43 disrupts the axonal transcriptome of motoneurons accompanied by impaired axonal translation and mitochondria function. Acta Neuropathol. Commun. 2020;8:116. doi: 10.1186/s40478-020-00987-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-020-00987-6</ArticleId><ArticleId IdType="pmc">PMC7379803</ArticleId><ArticleId IdType="pubmed">32709255</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvatori I, et al. Differential toxicity of TAR DNA-binding protein 43 isoforms depends on their submitochondrial localization in neuronal cells. J. Neurochem. 2018;146:585&#x2013;597. doi: 10.1111/jnc.14465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14465</ArticleId><ArticleId IdType="pubmed">29779213</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat. Med. 2016;22:869&#x2013;878. doi: 10.1038/nm.4130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4130</ArticleId><ArticleId IdType="pmc">PMC4974139</ArticleId><ArticleId IdType="pubmed">27348499</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis SA, et al. TDP-43 interacts with mitochondrial proteins critical for mitophagy and mitochondrial dynamics. Neurosci. Lett. 2018;678:8&#x2013;15. doi: 10.1016/j.neulet.2018.04.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2018.04.053</ArticleId><ArticleId IdType="pmc">PMC5975202</ArticleId><ArticleId IdType="pubmed">29715546</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofalo S, et al. Natural killer cells modulate motor neuron-immune cell cross talk in models of Amyotrophic Lateral Sclerosis. Nat. Commun. 2020;11:1773. doi: 10.1038/s41467-020-15644-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15644-8</ArticleId><ArticleId IdType="pmc">PMC7156729</ArticleId><ArticleId IdType="pubmed">32286313</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques RF, et al. Motor neuron translatome reveals deregulation of SYNGR4 and PLEKHB1 in mutant TDP-43 amyotrophic lateral sclerosis models. Hum. Mol. Genet. 2020;29:2647&#x2013;2661. doi: 10.1093/hmg/ddaa140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddaa140</ArticleId><ArticleId IdType="pmc">PMC7530531</ArticleId><ArticleId IdType="pubmed">32686835</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr BO, et al. Presynaptic homeostasis opposes disease progression in mouse models of ALS-like degeneration: Evidence for homeostatic neuroprotection. Neuron. 2020;107:95&#x2013;111.e116. doi: 10.1016/j.neuron.2020.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.04.009</ArticleId><ArticleId IdType="pmc">PMC7529479</ArticleId><ArticleId IdType="pubmed">32380032</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Cueto C, et al. Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis. Brain Pathol. 2021;31:e12972. doi: 10.1111/bpa.12972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12972</ArticleId><ArticleId IdType="pmc">PMC8549023</ArticleId><ArticleId IdType="pubmed">33983653</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CH, et al. TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell. 2020;183:636&#x2013;649.e618. doi: 10.1016/j.cell.2020.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.020</ArticleId><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl. Acad. Sci. USA. 2013;110:E736&#x2013;745. doi: 10.1073/pnas.1222809110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222809110</ArticleId><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Goossens J, et al. TDP-43 as a possible biomarker for frontotemporal lobar degeneration: A systematic review of existing antibodies. Acta Neuropathol. Commun. 2015;3:15. doi: 10.1186/s40478-015-0195-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-015-0195-1</ArticleId><ArticleId IdType="pmc">PMC4380254</ArticleId><ArticleId IdType="pubmed">25853864</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H, et al. Understanding and managing metabolic dysfunction in amyotrophic lateral sclerosis. Expert Rev. Neurother. 2020;20:907&#x2013;919. doi: 10.1080/14737175.2020.1788389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2020.1788389</ArticleId><ArticleId IdType="pubmed">32583696</ArticleId></ArticleIdList></Reference><Reference><Citation>Cistaro A, et al. The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. Eur. J. Nucl. Med. Mol. Imaging. 2014;41:844&#x2013;852. doi: 10.1007/s00259-013-2667-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-013-2667-5</ArticleId><ArticleId IdType="pubmed">24445987</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, et al. Untargeted metabolomics yields insight into ALS disease mechanisms. J. Neurol. Neurosurg. Psychiatry. 2020 doi: 10.1136/jnnp-2020-323611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323611</ArticleId><ArticleId IdType="pmc">PMC7677469</ArticleId><ArticleId IdType="pubmed">32928939</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawaid A, Khan R, Polymenidou M, Schulz PE. Disease-modifying effects of metabolic perturbations in ALS/FTLD. Mol Neurodegener. 2018;13:63. doi: 10.1186/s13024-018-0294-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0294-0</ArticleId><ArticleId IdType="pmc">PMC6278047</ArticleId><ArticleId IdType="pubmed">30509290</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Ghosh D, Singh RL. Amyotrophic lateral sclerosis and metabolomics: Clinical implication and therapeutic approach. J. Biomark. 2013;2013:538765. doi: 10.1155/2013/538765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/538765</ArticleId><ArticleId IdType="pmc">PMC4437352</ArticleId><ArticleId IdType="pubmed">26317018</ArticleId></ArticleIdList></Reference><Reference><Citation>Palamiuc L, et al. A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol. Med. 2015;7:526&#x2013;546. doi: 10.15252/emmm.201404433.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201404433</ArticleId><ArticleId IdType="pmc">PMC4492815</ArticleId><ArticleId IdType="pubmed">25820275</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn FJ, et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J. Neurol. Neurosurg. Psychiatry. 2018;89:1016&#x2013;1023. doi: 10.1136/jnnp-2017-317887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317887</ArticleId><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorne T, De Bock K, Van Den Bosch L. Energy metabolism in ALS: An underappreciated opportunity? Acta Neuropathol. 2018;135:489&#x2013;509. doi: 10.1007/s00401-018-1835-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1835-x</ArticleId><ArticleId IdType="pmc">PMC5978930</ArticleId><ArticleId IdType="pubmed">29549424</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton KA, et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph. Lateral Scler. Frontotemporal Degener. 2014;15:362&#x2013;370. doi: 10.3109/21678421.2014.908311.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.908311</ArticleId><ArticleId IdType="pubmed">24984169</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo E, et al. Medium-chain fatty acids, beta-hydroxybutyric acid and genetic modulation of the carnitine shuttle are protective in a Drosophila model of ALS based on TDP-43. Front. Mol. Neurosci. 2018;11:182. doi: 10.3389/fnmol.2018.00182.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00182</ArticleId><ArticleId IdType="pmc">PMC5990617</ArticleId><ArticleId IdType="pubmed">29904341</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiduschat N, et al. Motor cortex glutathione deficit in ALS measured in vivo with the J-editing technique. Neurosci. Lett. 2014;570:102&#x2013;107. doi: 10.1016/j.neulet.2014.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2014.04.020</ArticleId><ArticleId IdType="pubmed">24769125</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi L, Ke Y, Luo C, Gozal D, Liu R. Depletion of reduced glutathione enhances motor neuron degeneration in vitro and in vivo. Neuroscience. 2007;144:991&#x2013;1003. doi: 10.1016/j.neuroscience.2006.09.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2006.09.064</ArticleId><ArticleId IdType="pmc">PMC1944995</ArticleId><ArticleId IdType="pubmed">17150307</ArticleId></ArticleIdList></Reference><Reference><Citation>Poli G, Albano E, Dianzani MU. The role of lipid peroxidation in liver damage. Chem. Phys. Lipids. 1987;45:117&#x2013;142. doi: 10.1016/0009-3084(87)90063-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0009-3084(87)90063-6</ArticleId><ArticleId IdType="pubmed">3319224</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain A, Martensson J, Stole E, Auld PA, Meister A. Glutathione deficiency leads to mitochondrial damage in brain. Proc. Natl. Acad. Sci. USA. 1991;88:1913&#x2013;1917. doi: 10.1073/pnas.88.5.1913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.88.5.1913</ArticleId><ArticleId IdType="pmc">PMC51136</ArticleId><ArticleId IdType="pubmed">2000395</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: The in vivo evidence. Cell Metab. 2018;27:529&#x2013;547. doi: 10.1016/j.cmet.2018.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2018.02.011</ArticleId><ArticleId IdType="pmc">PMC6342515</ArticleId><ArticleId IdType="pubmed">29514064</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong B, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol. Aging. 2013;34:1581&#x2013;1588. doi: 10.1016/j.neurobiolaging.2012.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.12.005</ArticleId><ArticleId IdType="pmc">PMC3632303</ArticleId><ArticleId IdType="pubmed">23312803</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y, et al. NAD(+) supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc. Natl. Acad. Sci. USA. 2018;115:E1876&#x2013;E1885. doi: 10.1073/pnas.1718819115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1718819115</ArticleId><ArticleId IdType="pmc">PMC5828618</ArticleId><ArticleId IdType="pubmed">29432159</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino V, et al. Enhancing mitochondrial proteostasis reduces amyloid-beta proteotoxicity. Nature. 2017;552:187&#x2013;193. doi: 10.1038/nature25143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature25143</ArticleId><ArticleId IdType="pmc">PMC5730497</ArticleId><ArticleId IdType="pubmed">29211722</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei CC, et al. Nicotinamide mononucleotide attenuates brain injury after intracerebral hemorrhage by activating Nrf2/HO-1 signaling pathway. Sci. Rep. 2017;7:717. doi: 10.1038/s41598-017-00851-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-00851-z</ArticleId><ArticleId IdType="pmc">PMC5429727</ArticleId><ArticleId IdType="pubmed">28386082</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan BA, Pehar M, Killoy KM, Vargas MR. Enhanced SIRT6 activity abrogates the neurotoxic phenotype of astrocytes expressing ALS-linked mutant SOD1. FASEB J. 2019;33:7084&#x2013;7091. doi: 10.1096/fj.201802752R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201802752R</ArticleId><ArticleId IdType="pmc">PMC6529338</ArticleId><ArticleId IdType="pubmed">30841754</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan BA, et al. Enhancing NAD+ salvage pathway reverts the toxicity of primary astrocytes expressing amyotrophic lateral sclerosis-linked mutant superoxide dismutase 1 (SOD1) J. Biol. Chem. 2016;291:10836&#x2013;10846. doi: 10.1074/jbc.M115.698779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.698779</ArticleId><ArticleId IdType="pmc">PMC4865928</ArticleId><ArticleId IdType="pubmed">27002158</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlan BA, et al. Evaluation of the NAD(+) biosynthetic pathway in ALS patients and effect of modulating NAD(+) levels in hSOD1-linked ALS mouse models. Exp. Neurol. 2020;327:113219. doi: 10.1016/j.expneurol.2020.113219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2020.113219</ArticleId><ArticleId IdType="pmc">PMC7089832</ArticleId><ArticleId IdType="pubmed">32014438</ArticleId></ArticleIdList></Reference><Reference><Citation>Genc B, et al. Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP-43 pathology. Clin. Transl. Med. 2021;11:e336. doi: 10.1002/ctm2.336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.336</ArticleId><ArticleId IdType="pmc">PMC7898037</ArticleId><ArticleId IdType="pubmed">33634973</ArticleId></ArticleIdList></Reference><Reference><Citation>Dervishi I, Ozdinler PH. Incorporating upper motor neuron health in ALS drug discovery. Drug Discov. Today. 2018;23:696&#x2013;703. doi: 10.1016/j.drudis.2018.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2018.01.027</ArticleId><ArticleId IdType="pmc">PMC5849515</ArticleId><ArticleId IdType="pubmed">29331501</ArticleId></ArticleIdList></Reference><Reference><Citation>Genc B, Ozdinler PH. Moving forward in clinical trials for ALS: Motor neurons lead the way please. Drug Discov. Today. 2014;19:441&#x2013;449. doi: 10.1016/j.drudis.2013.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2013.10.014</ArticleId><ArticleId IdType="pmc">PMC4000750</ArticleId><ArticleId IdType="pubmed">24171950</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom AJ, et al. Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients. Mol. Neurodegener. 2022;17:1. doi: 10.1186/s13024-021-00511-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00511-x</ArticleId><ArticleId IdType="pmc">PMC8739729</ArticleId><ArticleId IdType="pubmed">34991663</ArticleId></ArticleIdList></Reference><Reference><Citation>Figley MD, et al. SARM1 is a metabolic sensor activated by an increased NMN/NAD(+) ratio to trigger axon degeneration. Neuron. 2021;109:1118&#x2013;1136.e1111. doi: 10.1016/j.neuron.2021.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.02.009</ArticleId><ArticleId IdType="pmc">PMC8174188</ArticleId><ArticleId IdType="pubmed">33657413</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmaeili MA, Panahi M, Yadav S, Hennings L, Kiaei M. Premature death of TDP-43 (A315T) transgenic mice due to gastrointestinal complications prior to development of full neurological symptoms of amyotrophic lateral sclerosis. Int. J. Exp. Pathol. 2013;94:56&#x2013;64. doi: 10.1111/iep.12006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iep.12006</ArticleId><ArticleId IdType="pmc">PMC3575874</ArticleId><ArticleId IdType="pubmed">23317354</ArticleId></ArticleIdList></Reference><Reference><Citation>Coughlan KS, Halang L, Woods I, Prehn JH. A high-fat jelly diet restores bioenergetic balance and extends lifespan in the presence of motor dysfunction and lumbar spinal cord motor neuron loss in TDP-43A315T mutant C57BL6/J mice. Dis. Model Mech. 2016;9:1029&#x2013;1037. doi: 10.1242/dmm.024786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dmm.024786</ArticleId><ArticleId IdType="pmc">PMC5047697</ArticleId><ArticleId IdType="pubmed">27491077</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdewyn S, et al. Prevention of intestinal obstruction reveals progressive neurodegeneration in mutant TDP-43 (A315T) mice. Mol. Neurodegener. 2014;9:24. doi: 10.1186/1750-1326-9-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-9-24</ArticleId><ArticleId IdType="pmc">PMC4088917</ArticleId><ArticleId IdType="pubmed">24938805</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong H, et al. Metabolic determinants of cellular fitness dependent on mitochondrial reactive oxygen species. Sci. Adv. 2020 doi: 10.1126/sciadv.abb7272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abb7272</ArticleId><ArticleId IdType="pmc">PMC7673681</ArticleId><ArticleId IdType="pubmed">33148642</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai R, Waguri S. Improved electron microscopy fixation methods for tracking autophagy-associated membranes in cultured mammalian cells. Methods Mol. Biol. 2019;1880:211&#x2013;221. doi: 10.1007/978-1-4939-8873-0_13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-8873-0_13</ArticleId><ArticleId IdType="pubmed">30610699</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>